Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study

详细信息    查看全文

• 作者：Huang-Tz Ou ; Kai-Cheng Chang ; Chung-Yi Li ; Jin-Shang Wu
• 关键词：Type 2 diabetes mellitus ; Dipeptidyl peptidase ; 4 inhibitors ; Cardiovascular diseases ; Antidiabetic drugs ; Hypoglycemia
• 刊名：Cardiovascular Diabetology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：15
• 期：1
• 全文大小：851 KB
• 刊物主题：Diabetes; Angiology; Cardiology;
• 出版者：BioMed Central
• ISSN：1475-2840

文摘

Background Several antidiabetic drugs (i.e., sulfonylureas; SU, rosiglitazone) have been reported to be associated with increased risks of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 inhibitors (DPP4i) are newly available antidiabetic drugs. Most studies only compared DPP4i with a placebo or SU, or targeted a specific CVD event of interest (i.e., heart failure; HF). Comparative research of CVD risks of DPP4i with other antidiabetic drugs (i.e., metformin, thiazolidinediones, meglitinides, acarbose, and insulin) remains scarce. This study was aimed to assess comparative risks of CVD, including ischemic stroke, myocardial infarction (MI) and HF, and hypoglycemia of DPP4i with other antidiabetic drugs.